ALHC vs. REGN: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and REGN, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
REGN stands out with 64.18 billion USD in market value—about 21.16× ALHC’s market cap of 3.03 billion USD.
ALHC’s beta of 1.33 points to much larger expected swings compared to REGN’s calmer 0.43, suggesting both higher upside and downside potential.
| Symbol | ALHC | REGN |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | Regeneron Pharmaceuticals, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Biotechnology |
| CEO | Mr. John E. Kao | Dr. Leonard S. Schleifer M.D., Ph.D. |
| Price | 15.33 USD | 604.62 USD |
| Market Cap | 3.03 billion USD | 64.18 billion USD |
| Beta | 1.33 | 0.43 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | March 26, 2021 | April 2, 1991 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALHC and REGN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and REGN based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALHC posts a negative P/E of -32.75, reflecting last year’s net loss, while REGN at 14.34 signals healthy earnings.
- ALHC posts a negative forward PEG of -1.11, hinting at anticipated earnings decline, whereas REGN at 1.09 has projections for stable or growing earnings.
| Symbol | ALHC | REGN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -32.75 | 14.34 |
| Forward PEG Ratio (TTM) | -1.11 | 1.09 |
| Price-to-Sales Ratio (P/S, TTM) | 1.01 | 4.56 |
| Price-to-Book Ratio (P/B, TTM) | 27.45 | 2.20 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | 21.25 |
| EV-to-EBITDA (TTM) | -64.47 | 12.81 |
| EV-to-Sales (TTM) | 0.86 | 4.53 |
| EV-to-Free Cash Flow (TTM) | 136.01 | 21.12 |
Dividend Comparison
ALHC offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while REGN provides a 0.29% dividend yield, giving investors a steady income stream.
| Symbol | ALHC | REGN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.29% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and REGN, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- With negative EBIT (-2.98), ALHC cannot cover its interest payments. REGN, with an interest coverage of 98.59, meets its interest obligations.
| Symbol | ALHC | REGN |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 4.93 |
| Quick Ratio (TTM) | 1.69 | 4.03 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 0.09 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.07 |
| Interest Coverage Ratio (TTM) | -2.98 | 98.59 |